Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Zacks News
DGX vs. AMED: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. AMED: Which Stock Is the Better Value Option?
Here's Why You Should Add Ensign Group to Your Portfolio
by Zacks Equity Research
Strategic initiatives and a healthy balance sheet make Ensign Group (ENSG) an attractive pick for investors.
Amedisys (AMED) Up 2.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Broadens Hospice Base With AseraCare Buyout
by Zacks Equity Research
Amedisys (AMED) expects AseraCare business to add greater scale to its existing nationwide network.
Hospital Industry's Dull Near-Term Outllook Induced by Coronavirus
by Sapna Bagaria
Revenue loss and cost rise due to coronavirus outbreak put hospital companies in a tight spot.
The Zacks Analyst Blog Highlights: Brookdale Senior Living, The Ensign Group, Amedysis and Chemed
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Brookdale Senior Living, The Ensign Group, Amedysis and Chemed
Silver Tsunami to Hit the United States: 4 Stocks in Focus
by Aparajita Dutta
There are approximately 35 million Americans aged 65 or older currently and this number is expected to double in the next 25 years.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Amedisys (AMED) Q1 Earnings Beat, Operating Margin Falls
by Zacks Equity Research
Amedisys (AMED) notes that COVID-19 started impacting its volumes and costs beginning the second half of March.
Amedisys (AMED) Beats Q1 Earnings Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 8.25% and -4.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: Vertex Pharmaceuticals, Alibaba, Amedisys and Fabrinet
by Zacks Equity Research
Zacks.com featured highlights include: Vertex Pharmaceuticals, Alibaba, Amedisys and Fabrinet
Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio
by Sumit Singh
Interest Coverage Ratio suggests how many times the interest could be paid from earnings and gauges the margin of safety a firm has for paying interest.
Zacks.com featured highlights include: NEE, FNV, AMED, ATO and COST
by Zacks Equity Research
Zacks.com featured highlights include: NEE, FNV, AMED, ATO and COST
Bet on These 5 Low Leverage Stocks to Avoid Huge Losses
by Zacks Equity Research
With the earnings season in full swing, the real challenge for an investor is determining whether an organization's debt level is sustainable.
Earnings Preview: Amedisys (AMED) Q1 Earnings Expected to Decline
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Quest Diagnostics (DGX) in Focus: Stock Moves 5.4% Higher
by Zacks Equity Research
Quest Diagnostics (DGX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Add These 4 Stocks With Remarkable Interest Coverage Ratio
by Sumit Singh
Debt, which is crucial for most of the companies to finance operations, comes at a cost called interest. Interest expense has a direct bearing on the profits of a company.
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AMED) Outperforming Other Medical Stocks This Year?
Bet on These 5 Low Leverage Stocks as Q1 Earnings Starts
by Zacks Equity Research
To safeguard one's portfolio from notable losses, the real challenge for an investor is determining whether the organization's debt level is sustainable. A debt-free corporation is hard to find.
Amedisys (AMED) Is Up 8.62% in One Week: What You Should Know
by Zacks Equity Research
Does Amedisys (AMED) have what it takes to be a top stock pick for momentum investors? Let's find out.
Amedisys (AMED) Upgraded to Buy: Here's Why
by Zacks Equity Research
Amedisys (AMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amedisys (AMED) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Amedisys (AMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Amedisys Gains on Expanding Hospice Arm, Favorable Demography
by Zacks Equity Research
Amedisys' (AMED) recent acquisitions in the Hospice arm aid the company's growth.
Amedisys (AMED) Stock Moves -0.87%: What You Should Know
by Zacks Equity Research
In the latest trading session, Amedisys (AMED) closed at $168.20, marking a -0.87% move from the previous day.